Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2020

09.03.2020 | Original Article

Impact of a reduction in follow-up frequency on life expectancy in uterine cervical cancer patients

verfasst von: Yuri Matsumoto, Seiji Mabuchi, Fumiaki Isohashi, Naoko Komura, Kazuhiko Ogawa, Tadashi Kimura

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The appropriate interval of post-treatment follow-up appointments for uterine cervical cancer is unclear. The aim of this study was to investigate the impact of reducing the frequency of post-treatment follow-up examinations on life expectancy and medical expenses in cervical cancer patients.

Methods

Cervical cancer patients who were treated with radiotherapy between 2008 and 2017, underwent a less frequent follow-up program, and subsequently developed recurrent disease were included in consecutive group (CG). Non-randomized groups of cervical cancer patients who underwent a frequent follow-up program after radiotherapy between 1997 and 2007, and subsequently developed recurrent disease were also identified through a chart review and served as a comparison group (primary group [PG]). Clinical data regarding the primary disease, follow-up, recurrence, and survival were collected. Univariate and multivariate analyses of predictors of survival were performed.

Results

A total of 263 recurrent cervical cancer patients (PG: 154, CG: 109) were included in the current study. A reduction in follow-up frequency of up to 40% did not increase the frequency of symptomatic recurrence (PG: vs. CG: 31.2% vs. 35.8%, p = 0.43) or reduce the median overall survival periods of recurrent cervical cancer patients (PG vs. CG: 32 months vs. 36 months, p = 0.15). However, the reduction in the follow-up frequency significantly reduced follow-up costs.

Conclusion

Reducing the frequency of follow-up by up to 40% did not result in shorter overall survival compared with a conventional follow-up program. The results of this study provide a rationale for future studies investigating the optimal follow-up schedule for patients with cervical cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
3.
Zurück zum Zitat Leath CA 3rd, Straughn JM Jr (2013) Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129:251–257CrossRefPubMed Leath CA 3rd, Straughn JM Jr (2013) Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 129:251–257CrossRefPubMed
4.
Zurück zum Zitat Rustin GJ, van der Burg ME, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155–1163CrossRefPubMed Rustin GJ, van der Burg ME, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155–1163CrossRefPubMed
7.
Zurück zum Zitat Mabuchi S, Isohashi F, Yoshioka Y et al (2010) Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer 20:834–840CrossRefPubMed Mabuchi S, Isohashi F, Yoshioka Y et al (2010) Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer 20:834–840CrossRefPubMed
8.
Zurück zum Zitat Mabuchi S, Isohashi F, Maruoka S et al (2012) Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet 286:179–185CrossRefPubMed Mabuchi S, Isohashi F, Maruoka S et al (2012) Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy. Arch Gynecol Obstet 286:179–185CrossRefPubMed
9.
Zurück zum Zitat Fujiwara Y, Yonemori K, Shibata T et al (2015) Japanese universal health care faces a crisis in cancer treatment. Lancet Oncol 16:251–252CrossRefPubMed Fujiwara Y, Yonemori K, Shibata T et al (2015) Japanese universal health care faces a crisis in cancer treatment. Lancet Oncol 16:251–252CrossRefPubMed
10.
Zurück zum Zitat Mabuchi S, Morishige K, Isohashi F et al (2009) Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol 115:482–487CrossRefPubMed Mabuchi S, Morishige K, Isohashi F et al (2009) Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol 115:482–487CrossRefPubMed
11.
Zurück zum Zitat Mabuchi S, Isohashi F, Yokoi T et al (2016) A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol 141:240–246CrossRefPubMed Mabuchi S, Isohashi F, Yokoi T et al (2016) A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol 141:240–246CrossRefPubMed
12.
Zurück zum Zitat Mabuchi S, Ugaki H, Isohashi F et al (2010) Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest 69:224–232CrossRefPubMed Mabuchi S, Ugaki H, Isohashi F et al (2010) Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone. Gynecol Obstet Invest 69:224–232CrossRefPubMed
14.
Zurück zum Zitat Mabuchi S, Takahashi R, Isohashi F et al (2014) Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer 24:141–148CrossRefPubMed Mabuchi S, Takahashi R, Isohashi F et al (2014) Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer 24:141–148CrossRefPubMed
15.
Zurück zum Zitat Mabuchi S, Morishige K, Fujita M et al (2009) The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol 113:200–204CrossRefPubMed Mabuchi S, Morishige K, Fujita M et al (2009) The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol 113:200–204CrossRefPubMed
16.
Zurück zum Zitat Mabuchi S, Matsumoto Y, Komura N et al (2017) The efficacy of surgical treatment of recurrent or persistent cervical cancer that develops in a previously irradiated field: a monoinstitutional experience. Int J Clin Oncol 22:927–936CrossRefPubMed Mabuchi S, Matsumoto Y, Komura N et al (2017) The efficacy of surgical treatment of recurrent or persistent cervical cancer that develops in a previously irradiated field: a monoinstitutional experience. Int J Clin Oncol 22:927–936CrossRefPubMed
17.
Zurück zum Zitat Mabuchi S, Kozasa K, Kimura T (2017) Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer. Int J Gynaecol Obstet 139:185–191CrossRefPubMed Mabuchi S, Kozasa K, Kimura T (2017) Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer. Int J Gynaecol Obstet 139:185–191CrossRefPubMed
20.
Zurück zum Zitat Bodurka-Bevers D, Morris M, Eifel PJ et al (2000) Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78:187–193CrossRefPubMed Bodurka-Bevers D, Morris M, Eifel PJ et al (2000) Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78:187–193CrossRefPubMed
21.
Zurück zum Zitat Esajas MD, Duk JM, de Bruijn HW et al (2001) Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 19:3960–3966CrossRefPubMed Esajas MD, Duk JM, de Bruijn HW et al (2001) Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 19:3960–3966CrossRefPubMed
22.
Zurück zum Zitat Duyn A, Van Eijkeren M, Kenter G et al (2002) Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand 81:759–763CrossRefPubMed Duyn A, Van Eijkeren M, Kenter G et al (2002) Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand 81:759–763CrossRefPubMed
23.
Zurück zum Zitat Lim KC, Howells RE, Evans AS (2004) The role of clinical follow up in early stage cervical cancer in South Wales. BJOG 111:1444–1448CrossRefPubMed Lim KC, Howells RE, Evans AS (2004) The role of clinical follow up in early stage cervical cancer in South Wales. BJOG 111:1444–1448CrossRefPubMed
24.
Zurück zum Zitat Morice P, Deyrolle C, Rey A et al (2004) Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 15:218–223CrossRefPubMed Morice P, Deyrolle C, Rey A et al (2004) Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 15:218–223CrossRefPubMed
25.
Zurück zum Zitat Sartori E, Pasinetti B, Carrara L et al (2007) Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 107(1 Suppl 1):S241–247CrossRefPubMed Sartori E, Pasinetti B, Carrara L et al (2007) Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 107(1 Suppl 1):S241–247CrossRefPubMed
26.
Zurück zum Zitat Zola P, Fuso L, Mazzola S et al (2007) Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol 107(1 Suppl 1):S150–154CrossRefPubMed Zola P, Fuso L, Mazzola S et al (2007) Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol 107(1 Suppl 1):S150–154CrossRefPubMed
27.
Zurück zum Zitat Hillesheim I, Limone GA, Klimann L et al (2017) Cervical cancer posttreatment follow-up: critical analysis. Int J Gynecol Cancer 27:1747–1752CrossRefPubMed Hillesheim I, Limone GA, Klimann L et al (2017) Cervical cancer posttreatment follow-up: critical analysis. Int J Gynecol Cancer 27:1747–1752CrossRefPubMed
28.
Zurück zum Zitat Utada M, Chernyavskiy P, Lee WJ et al (2019) Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer 144:2144–2152CrossRefPubMed Utada M, Chernyavskiy P, Lee WJ et al (2019) Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer 144:2144–2152CrossRefPubMed
29.
Zurück zum Zitat Jeppesen MM, Mogensen O, Hansen DG et al (2017) Detection of recurrence in early stage endometrial cancer—the role of symptoms and routine follow-up. Acta Oncol 56:262–269CrossRefPubMed Jeppesen MM, Mogensen O, Hansen DG et al (2017) Detection of recurrence in early stage endometrial cancer—the role of symptoms and routine follow-up. Acta Oncol 56:262–269CrossRefPubMed
30.
Zurück zum Zitat Forni F, Ferrandina G, Deodato F et al (2007) Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys 69:1145–1149CrossRefPubMed Forni F, Ferrandina G, Deodato F et al (2007) Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys 69:1145–1149CrossRefPubMed
31.
Zurück zum Zitat Chan YM, Ng TY, Ngan HY et al (2002) Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 84:7–11CrossRefPubMed Chan YM, Ng TY, Ngan HY et al (2002) Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 84:7–11CrossRefPubMed
Metadaten
Titel
Impact of a reduction in follow-up frequency on life expectancy in uterine cervical cancer patients
verfasst von
Yuri Matsumoto
Seiji Mabuchi
Fumiaki Isohashi
Naoko Komura
Kazuhiko Ogawa
Tadashi Kimura
Publikationsdatum
09.03.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01641-w

Weitere Artikel der Ausgabe 6/2020

International Journal of Clinical Oncology 6/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.